



an Open Access Journal by MDPI

Pancreatic Cancer Heterogeneity and Therapeutic Implications

Guest Editor:

Dr. Tatjana Arsenijevic

1. Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, 1070 Brussels, Belgium

2. Department of Gastroenterology, Hepatology and Digestive Oncology, Hopital Universitaire de Bruxelles H.U.B. CUB Hopital Erasme, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Brussels, Belgium

Deadline for manuscript submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear colleagues,

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer with an abysmal prognosis and a 5-year overall survival of 9%. The only potential cure is surgery, but few patients present with resectable tumors at the time of diagnosis, which is often delayed by the vagueness of symptoms and the lack of specific clinical markers for early stages of PDAC. PDAC is also among the most chemoresistant cancers. Major obstacles to the effective treatment of patients with pancreatic cancer are its high heterogeneity translated in a diverse pattern of clinical outcomes and responses to therapies. There is a remarkably high histological heterogeneity between the PDAC tumors (intertumoral heterogeneity), but also within a single tumor (intratumoral heterogeneity).

We welcome original and review papers that focus on the recent advances in the field of pancreatic cancer research, covering but not limited to 1) molecular insights of PDAC heterogeneity, 2) molecular mechanisms of innate and acquired resistance to therapy 3) characterization of tumor-stroma crosstalk and 4) potential novel targeted therapies.

Dr. Tatjana Arsenijevic

Guest Editor



mdpi.com/si/162691



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI